gyrA_NP Mutations_NP Associated_NP with_IN Nalidixic_NP Acid-Resistant_NP Salmonellae_NP from_IN Wild_NP Birds_NP resistant_JJ isolates_NNS of_IN salmonellae_NNS has_VBZ been_VBN related_VBN to_TO the_DT use_NN of_IN antibiotics_NNS in_IN veterinary_JJ medicine_NN ,_, which_WDT causes_VBZ an_DT important_JJ impact_NN on_IN the_DT selection_NN of_IN resistance_NN ._SENT It_PP has_VBZ also_RB been_VBN demonstrated_VBN that_IN veterinary_JJ clones_NNS possess_VBP the_DT same_JJ mechanism_NN of_IN resistance_NN as_IN human_JJ clinical_JJ isolates_NNS ._SENT Quinolone_JJ resistance_NN in_IN salmonellae_NNS is_VBZ mainly_RB associated_VBN with_IN mutations_NNS in_IN the_DT quinolone_JJ resistance-determining_NN region_NN (_( QRDR_NP )_) of_IN the_DT gyrA_NN and_CC parC_NN genes_NNS ._SENT However_RB ,_, little_RB is_VBZ known_VBN about_IN what_WP the_DT incidence_NN of_IN resistance_NN in_IN wild_JJ animals_NNS is_VBZ and_CC which_WDT of_IN the_DT mechanisms_NNS of_IN resistance_NN these_DT strains_NNS have_VBP ,_, although_IN it_PP is_VBZ thought_VBN that_IN wild_JJ animals_NNS are_VBP also_RB integrated_VBN in_IN the_DT same_JJ epidemiologic_JJ cycle_NN ._SENT The_DT aim_NN of_IN this_DT study_NN was_VBD to_TO analyze_VB the_DT prevalence_NN of_IN quinolone-resistant_JJ isolates_NNS of_IN salmonellae_NNS from_IN wild_JJ birds_NNS and_CC determine_VB the_DT mechanisms_NNS involved_VBD ._SENT A_DT total_NN of_IN 45_CD Salmonella_NP enterica_NN subsp_NN ._SENT enterica_NN isolates_NNS were_VBD obtained_VBN from_IN stool_NN samples_NNS from_IN wild_JJ birds_NNS just_RB arrived_VBD to_TO GREFA_NP Wild_NP Life_NP Hospital_NP ._SENT Seven_CD strains_NNS (_( 15.5_CD %_NN )_) were_VBD selected_VBN on_IN the_DT basis_NN of_IN resistance_NN to_TO nalidixic_JJ acid_NN ._SENT The_DT MICs_NN of_IN nalidixic_JJ acid_NN (_( Sigma_NP Aldrich_NP ,_, Madrid_NP ,_, Spain_NP )_) ,_, ciprofloxacin_NN ,_, and_CC enrofloxacin_NP (_( Bayer_NP ,_, Leverkusen_NP ,_, Germany_NP )_) were_VBD measured_VBN by_IN a_DT twofold_JJ agar_NN dilution_NN method_NN and_CC interpreted_VBD according_VBG to_TO the_DT recommendations_NNS of_IN the_DT National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NP guidelines_NNS ._SENT To_TO identify_VB gyrA_NN and_CC parC_NN mutations_NNS in_IN resistant_JJ isolates_NNS ,_, PCR_NP and_CC direct_JJ DNA_NP sequencing_NP were_VBD performed_VBN as_RB follows_VBZ ._SENT A_DT 312-bp_JJ fragment_NN of_IN the_DT QRDR_NP of_IN the_DT gyrA_NN gene_NN was_VBD amplified_VBN from_IN a_DT genomic_JJ DNA_NN template_NN by_IN using_VBG specific_JJ primers_NNS gyr_NN A-1_NP (_( 5'-GGTACACCGTGCCGTACTTT-3_NP '_POS )_) and_CC gyr_NP A-2_NP (_( 5'-TCCACGAAATCCACCGTC-3_NP '_POS )_) corresponding_JJ to_TO positions_NNS 17_CD to_TO 137_CD and_CC 311_CD to_TO 328_CD ,_, respectively_RB ._SENT These_DT salmonella-specific_JJ primers_NNS were_VBD constructed_VBN on_IN the_DT basis_NN of_IN Salmonellaenterica_NP serotype_NP Typhimurium_NP gyrA_NP gene_NN sequence_NN data_NNS (_( GenBank_NP accession_NN number_NN )_) ._SENT The_DT primers_NNS for_IN the_DT amplification_NN of_IN the_DT QRDR_NP of_IN the_DT parC_NN gene_NN have_VBP been_VBN described_VBN elsewhere_RB ._SENT The_DT mutations_NNS in_IN the_DT gyrA_NN gene_NN leading_VBG to_TO the_DT amino_NN acid_NN substitutions_NNS and_CC MICs_NNS are_VBP shown_VBN in_IN Table_NP ._SENT TABLE_NN 1_CD :_: Susceptibility_NN to_TO quinolone_NP and_CC GyrA_NP substitutions_NNS of_IN S._NP enterica_NP subsp_NN ._SENT enterica_NN isolates_NNS from_IN wild_JJ birds_NNS Strains_NP S2_NP ,_, S9_NP ,_, S10_NP ,_, S14_NP ,_, and_CC S20_NP carried_VBD a_DT Cys-284->Ala_NP transversion_NN ,_, resulting_VBG in_IN a_DT Ser-83->Tyr_NP substitution_NN in_IN the_DT GyrA_NP subunit_NN ._SENT This_DT mutation_NN has_VBZ been_VBN described_VBN in_IN Salmonella_NP serotype_NN Typhimurium_NN strains_NNS resistant_JJ to_TO nalidixic_JJ acid_NN and_CC reduced_VBD the_DT susceptibility_NN to_TO fluoroquinolones_NNS isolated_VBN from_IN food-producing_NN animals_NNS ._SENT Strains_NNS S57_JJ and_CC S60_NP carried_VBD a_DT Gly-259->Cys_NP transition_NN ,_, resulting_VBG in_IN an_DT Asp-87->Asn_NP substitution_NN in_IN the_DT GyrA_NP subunit_NN ._SENT This_DT mutation_NN has_VBZ also_RB been_VBN described_VBN in_IN Salmonella_NP isolates_VBZ of_IN human_JJ and_CC animal_JJ origin_NN ._SENT No_DT mutations_NNS in_IN the_DT QRDR_NP of_IN parC_NN were_VBD detected_VBN ._SENT These_DT results_NNS may_MD confirm_VB that_IN parC_NN mutations_NNS are_VBP not_RB necessary_JJ to_TO obtain_VB a_DT high_JJ level_NN of_IN resistance_NN to_TO nalidixic_JJ acid_NN ._SENT The_DT mechanisms_NNS of_IN resistance_NN described_VBD here_RB are_VBP the_DT same_JJ as_IN the_DT ones_NNS described_VBN for_IN humans_NNS and_CC domestic_JJ animals_NNS ._SENT Therefore_RB ,_, it_PP is_VBZ possible_JJ that_IN wild_JJ animals_NNS be_VB included_VBN in_IN the_DT epidemiologic_JJ cycle_NN of_IN the_DT spread_NN of_IN resistance_NN and_CC the_DT dissemination_NN of_IN resistant_JJ bacteria_NNS among_IN animals_NNS and_CC the_DT environment_NN ._SENT Further_JJR studies_NNS are_VBP necessary_JJ to_TO obtain_VB more_JJR information_NN about_IN what_WP is_VBZ the_DT real_JJ role_NN of_IN wild_JJ animals_NNS in_IN these_DT facts_NNS ._SENT The_DT GenBank_NP accession_NN numbers_NNS for_IN the_DT partial_JJ sequences_NNS of_IN the_DT quinolone-resistant_JJ strains_NNS are_VBP ,_, ,_, ,_, ,_, ,_, ,_, and_NP ._SENT 